Angiotensin Converting Enzyme 2 News and Research

RSS

Nafamostat mesylate initially reduces SARS-CoV-2 viral loads in hamsters, study finds

Researchers have found that nafamostat mesylate, when injected in the nasal cavity of Syrian hamsters, can decrease initial SARS-CoV-2 viral loads in their nose. However, this effect was temporary and further testing is required to determine clinically significant effects. The research group's findings are available on the preprint server bioRxiv*.

11 Nov 2020

Endothelial cells resistant to SARS-CoV-2 infection

A team of scientists from Imperial College London has conducted a series of in vitro studies to investigate the susceptibility of endothelial cells to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the causative pathogen of coronavirus disease 2019 (COVID-19).

10 Nov 2020

Identifying SARS-CoV-2 spike protein mutations resistant to antibodies

Using a set of different monoclonal antibodies, researchers determined different mutations in the SARS-CoV-2 spike protein that leads to resistance. Understanding these resistant mutations is important in developing effective therapeutic strategies.

10 Nov 2020

ACE2 and TMPRSS2 not the only virus-receptors to mediate SARS-CoV-2 entry

However, a recent study published on the preprint server bioRxiv in November 2020 uncovers the major role played by the N-terminal domain of the SARS-CoV-2 virus in host infection. This could be of great use in measuring the usefulness of antibodies used in convalescent plasma therapy for COVID-19.

9 Nov 2020

Immune-evading variants can emerge in SARS-CoV-2, researchers warn

An international team of researchers has shown that a mutation within severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent responsible for the coronavirus disease 2019 (COVID-19) – enables the pathogen to evade antibody-mediated immunity while maintaining replication fitness and increasing viral loads.

9 Nov 2020

Study shows SARS-CoV-2 direct heart muscle cell infection, cell death, loss of contractility

In the study, published on the pre-print journal bioRxiv, the researchers revealed that SARS-CoV-2-infected EHTs manifested the typical characteristics of myocarditis or heart inflammation. These include the stimulation of immune cells, heart cell death, and decreased contractile force generation.

8 Nov 2020

SARS-CoV-2 viral antigens found in non-pulmonary tissues in recovering patients

A team of researchers in Singapore, led by Dr. Joe Yeong, and Prof. Tony Kiat Hon Lim, have reported the presence of residual SARS-CoV-2 ribonucleic acid (RNA) – the virus' genetic material – in stool samples and gastrointestinal tissues from patients recovering from the coronavirus disease 2019 (COVID-19).

8 Nov 2020

Innate immunity key to limiting viral load in COVID-19 cases

As the coronavirus disease 2019 (COVID-19) pandemic continues to cause many difficulties for public health authorities, research is ongoing to understand how the virus can cause fatal effects on those infected and thereby suggest effective preventive and therapeutic measures against it.

8 Nov 2020

Universal nanoparticle platform may help in rapid development of a COVID-19 vaccine

A research group in China recently published a paper on the pre-print server bioRxiv* that reports the performance of a potentially universal nanoparticle platform that may prove useful for the rapid development of a COVID-19 vaccine, as well as other vaccines in the future.

8 Nov 2020

Green tea and some fruit juices inhibit SARS-CoV-2 in vitro

Green tea, chokeberry juice, and pomegranate juice killed flu and SARS-CoV-2 viruses when incubated with the viruses in vitro. Thus, oral rinsing using these might be effective in preventing COVID-19.

5 Nov 2020

Computational study reveals SARS-CoV-2 spike protein structural stability

Using dynamic contact maps and energy differences between different conformations of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (or S-protein), an international team of researchers have recently published an article on the bioRxiv preprint server showing the different stable conformations of the spike protein.

4 Nov 2020

An analysis of genetic diversity of D614G mutation in SARS-CoV-2

A new study published in the preprint server bioRxiv in November 2020 reports that the effect of the mutation is minimal, in terms of pathogenicity or altered response to neutralizing antibodies elicited against the native virus strain.

4 Nov 2020

D614G mutation enhances stability of SARS-CoV-2 spike protein

A new study, published on the preprint server bioRxiv in November 2020 by researchers at the Indian Institute of Science, has explored this issue further. The researchers have found that this mutation is associated with structural and energetic changes that cause this spike variant to become more available during infection, thus rendering the associated strain more infective.

4 Nov 2020

Study shows brilacidin strongly inhibits SARS-CoV-2 in laboratory cell lines

A recent study by US researchers reveals that brilacidin, a small synthetic molecule with peptide-like properties, exerts potent in vitro antiviral activity against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – both as a standalone treatment and in combination with FDA-approved remdesivir. The study is currently available on the bioRxiv preprint server.

4 Nov 2020

Evidence of robust and persistent antibodies against SARS-CoV-2

A team of researchers from the Icahn School of Medicine at Mount Sinai, New York, have worked in collaboration to try and answer one of the most baffling questions surrounding the coronavirus disease 19 (COVID-19) pandemic: do antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) last after a primary infection?

3 Nov 2020

Rapid generation of divergent synthetic antibodies against SARS-CoV-2 in a cell-free engineering platform

In a groundbreaking bioRxiv paper, a research group from the Massachusetts Institute of Technology (MIT), Harvard University and Howard Hughes Medical Institute in the US engineered antibodies against the receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein by using a novel approach. In doing so, they also identified more than 800 predicted binder families.

3 Nov 2020

SARS-CoV-2 spike D614G variant exhibits enhanced replication and transmissibility

A team of scientists from Switzerland, Germany, and the USA has demonstrated that the S-614G variant can easily bind to the human angiotensin-converting enzyme 2 (ACE2), the cellular gateway of SARS-CoV-2. The variant also showed enhanced replication and transmissibility in animal models.

2 Nov 2020

5-amino levulinic acid inhibits SARS-CoV-2 infection in vitro

Researchers tested 5-amino levulinic acid in vitro in human-derived cells and found it prevents severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Because it is safe and ubiquitous in plants and animals, it could be a potential drug against SARS-CoV-2.

1 Nov 2020

SARS-CoV-2 spike proteins can directly impact the blood-brain barrier

Like a key, SARS-CoV-2 - the virus that causes coronavirus disease 2019 (COVID-19) - attaches to specific molecules on the host cell surface, opening gateways into the cell interior.

30 Oct 2020

MD65 IgG-YTE shows powerful post-exposure neutralization of SARS-CoV-2

A recent study published in the preprint server bioRxiv in October 2020 describes a reliable animal model to demonstrate the powerful capacity of human neutralizing mAbs directed against SARS-CoV-2 to prevent viral binding the host cell receptor and thus block infection. This indicates the lifesaving value of mAbs in severe COVID-19.

29 Oct 2020